Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil
Glenmark Pharmaceuticals Ltd · Press Release · 11 Sept 2026, 2:20 pm
Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., launched RYALTRIS Nasal Spray in Brazil on 11th Sep'26. Following ANVISA regulatory approval, it becomes Brazil's first olopatadine-containing intranasal combination therapy, treating moderate to severe allergic rhinitis in patients aged 12 and older. The launch targets a market where allergic rhinitis affects 20–30% of the population (40–60 million people). RYALTRIS, Glenmark's flagship globally commercialized branded innovative product, is currently approved in 57 markets worldwide, including the US, EU, UK, and China.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 · 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg · 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings · 10 Nov 2026
- Transcript of the Earnings Call · 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 · 06 Nov 2026
